Summary
Abbott Laboratories (ABT) announced significant corporate governance updates following its Annual Shareholder Meeting on April 24, 2026. A key development is the approval of the Abbott Laboratories 2026 Incentive Stock Program, which will replace the previous 2017 program. This new program allows for a broad range of equity-based awards to employees and non-employee directors, with a maximum of 140,000,000 shares available, plus additional shares from the prior program's unused reserves. The program's adoption was overwhelmingly approved by shareholders, indicating strong support for the company's long-term incentive strategy. Additionally, the Board of Directors has been expanded from twelve to thirteen members, effective April 24, 2026. Shareholders also re-elected the entire slate of directors and ratified the appointment of Ernst & Young LLP as the company's auditors. The compensation of named executive officers was approved in an advisory vote, reflecting shareholder confidence in management's remuneration practices. These changes underscore Abbott's commitment to robust governance and aligning executive incentives with shareholder interests.
Key Highlights
- 1Abbott shareholders overwhelmingly approved the new Abbott Laboratories 2026 Incentive Stock Program, replacing the 2017 program, with 95.82% of votes cast in favor.
- 2The 2026 Incentive Stock Program allows for various equity awards and has a reserve of up to 140,000,000 common shares.
- 3The Board of Directors size has been increased from twelve to thirteen members, effective April 24, 2026.
- 4All incumbent directors were re-elected by shareholders with substantial support.
- 5Shareholders ratified the appointment of Ernst & Young LLP as Abbott's independent auditors.
- 6An advisory vote to approve the compensation of named executive officers passed with 90.35% of votes cast in favor.
- 7The Abbott Laboratories 2026 Employee Stock Purchase Plan for Non-U.S. Employees was approved with strong support (99.33% of votes cast).